Vitrolife (STO:VITR) has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.
“The stem cell field is experiencing strong growth, not least since President Obama lifted the ban on research into certain stem cell lines,” says Tony Winslöf, Head of Business Development at Vitrolife. The collaboration with Cellartis comes at the right time to develop the stem cell products of tomorrow, meeting the scientific, regulatory and commercial demands of the future.
“Cellartis is a world-leading company with regard to competence above all in the field of pluripotent stem cells, and as such is a valuable resource in developing the right products for a rapidly growing market,” says Magnus Nilsson, Vitrolife’s CEO, who also points out that "stem cell culture is difficult and both Vitrolife and Cellartis have long experience of optimizing culture environments for sensitive cells."
Axxam and B'SYS partner to expand access to validated ion channel cell lines for high-throughput electrophysiology